FDA Says Celgene's Revlimid Tied To Higher Cancer Risks

Law360, Chicago (May 8, 2012, 3:54 PM EDT) -- The U.S. Food and Drug Administration said Monday that some newly diagnosed patients who received Celgene Corp.'s blood cancer treatment drug Revlimid are at an increased risk of developing certain new types of cancers.

On Monday, the regulator said that clinical trials conducted after Revlimid was approved showed that patients with newly diagnosed multiple myeloma — a cancer of the plasma cells — who took Revlimid had an increased risk of developing secondary primary cancers, compared with similar patients who received a placebo. Specifically, the trials...
To view the full article, register now.